Treatment outcomes and risk factors for severity and mortality in Clostridioides difficile infection: a single-center study in Thailand.|https://dx.doi.org/10.3855/jidc.20742
Fecal Microbiota-based therapies compared to Fecal Microbiota Transplantation for Preventing recurrent C. difficile Infection.|https://dx.doi.org/10.1016/j.cgh.2025.08.029
Bezlotoxumab for the prevention of recurrent Clostridioides difficile infection for patients with cancer.|https://dx.doi.org/10.20524/aog.2025.0994
Lipidomics, Microbiota, and Intestinal Clostridioides difficile Infection Outcome.|https://dx.doi.org/10.3390/ijms26178214
Assessment of chemical methods in the extraction of spore surface layers in Clostridioides difficile spores.|https://dx.doi.org/10.1128/msphere.00531-25
Activated PI3K Delta Syndrome: A Case Presentation and Literature Review.|https://dx.doi.org/10.7759/cureus.89884
Use of proximity ligation shotgun metagenomics to investigate the dynamics of plasmids and bacteriophages in the gut microbiome following fecal microbiota transplantation.|https://dx.doi.org/10.1080/19490976.2025.2559019
Fecal microbiota transplantation in recurrent Clostridioides difficile: Is greater methodological rigor and the analysis of other populations relevant?|https://dx.doi.org/10.1016/j.rgmxen.2025.09.022
Response to "Fecal microbiota transplantation in recurrent Clostridioides difficile: Is greater methodological rigor and the analysis of other populations relevant?".|https://dx.doi.org/10.1016/j.rgmxen.2025.09.023
De novo design of potent inhibitors of clostridial family toxins.|https://dx.doi.org/10.1073/pnas.2509329122
Patients, antibiotics and Clostridioides difficile: when your best friend becomes your worst enemy.|https://dx.doi.org/10.1093/jacamr/dlaf163
Efficacy of Fecal Microbiota Transplantation (FMT) Versus Standard Antibiotic Therapy in Recurrent Clostridioides difficile (CDI/rCDI) Infection: A Systematic Review and Meta-Analysis.|https://dx.doi.org/10.7759/cureus.90614
Unchecked Immunity to Unleashed Anarchy: A Case of Hemophagocytic Lymphohistiocytosis Following Combination Immune Checkpoint Inhibitor Therapy.|https://dx.doi.org/10.7759/cureus.90533
Gut power for better health: microbial therapeutics.|https://dx.doi.org/10.1097/MOG.0000000000001136
Microbiota-Based Therapies for Recurrent Clostridium difficile Infection: A Systematic Review of Their Efficacy and Safety.|https://dx.doi.org/10.7759/cureus.90737
Microbiomes in Health, Diseases and Therapeutics.|https://dx.doi.org/10.1016/j.amjmed.2025.09.002
The emerging view on the roles of butyrate in Clostridioides difficile pathogenesis.|https://dx.doi.org/10.1128/iai.00047-25
